ReviewMolecules (Basel, Switzerland)2026
Small-Molecule Modulation of the Circadian Clock in Cancer and Aging.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circadian rhythms are ~24 h cycles regulated by an internal molecular clock. Disruption of this timing system has been implicated in numerous diseases, including the advancement of cancers and declines in function associated with aging. In recent years, scientists have identified various small molecules that can modulate core circadian clock proteins and pathways, providing potential therapeutic strategies to correct circadian dysfunction. This review presents a thorough overview of circadian clock mechanisms and highlights known small-molecule modulators. We describe how these compounds were discovered (through high-throughput screening and rational design) and categorize them based on their molecular targets. This review also summarizes key findings in cancer models, where clock-modulating compounds affect tumor metabolism, cell proliferation, and responsiveness to treatments, as well as in aging models, where strengthening circadian function may enhance metabolic health and longevity. Additionally, we cover clinical and preclinical studies involving these molecules and address challenges such as off-target effects and the complex nature of clock regulation. Finally, we outline future directions, emphasizing the development of new chronotherapeutics and the incorporation of circadian modulation into interventions for cancer and aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.